C. difficile 위험도


Complicated SSTI, intraabdominal infectionCAP100 mg IV 1 dose, then 50 mg IV q12h x5-14d100 mg IV dose, then 50 mg IV q12h x7-14dNo renal dose adjustment

Usual doseUse in pediatric patients <8y of age is not recommended because of the effect on tooth development

Safety and efficacy in pediatric patients <18y of age have not been established- Age 8-11y without alternative option: 1.2 mg/kg IV q12h (max 50 mg/dose)

  • Age 12-18y without alternative option: 50 mg IV q12hNo renal dose adjustment

Mild or moderate hepatic impairmentSevere hepatic impairmentNo dosage adjustment100 mg IV loading, then 25 mg IV q12h

General Information

Reserved for highly resistant infections or when significant allergies restrict other options and when there is documented susceptibility.

Black Box Warning: Associated with more treatment failures than alternatives and excess mortality. Tigecycline should be reserved for use in situations when alternative treatments are not suitable.

Perform bacteriological examination and sensitivity testing during initiation and for suspected relapse.

Monitor hepatic function for patients with abnormal liver function test, and severe hepatic impairment.

Obtain baseline blood coagulation panel, including fibrinogen, and monitor regularly during treatment.


  • Abdominal pain

  • Diarrhea

  • Nausea

  • Vomiting

  • Headache


  • Septic shock

  • Acute pancreatitis

  • Clostridioides difficile infection

  • Increased liver enzymes

  • Hyperbilirubinemia

  • Liver failure

  • Pseudotumor cerebri

  • Sepsis

  • Anaphylaxis


  • Acitretin - may result in increased risk of pseudotumor cerebri


  • Penicillins

  • Retinoids

  • Cholera vaccine, live

  • Oral contraceptives

Antimicrobial class: Tetracycline derivative, Glycylcycline

Pregnancy category: D

Average serum half life: 42 hours

Biliary penetration: Therapeutic

Lung penetration: Therapeutic

Requires Infectious Disease consultation.

Documented safety concerns in bacteremia especially.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.